

Incannex Appoints Dr Paul Liknaitzky as a Scientific Officer Advising the Board of Directors

Clinical stage cannabinoid development company, Incannex Healthcare Limited (ASX: IHL, 'Incannex' or the 'Company'), is pleased to announce that Dr Paul Liknaitzky PhD has formally joined the Company's Medical Advisory Board as a scientific officer for a minimum term of 18 months, with a period of exclusivity.

Dr Liknaitzky has been engaged to advise on the research of novel psychiatric agents and associated therapies that are potentially suitable for use in the treatment of anxiety and depression-related illnesses. Existing pharmacological options in the field of anxiety and depression treatment are limited in terms of inadequate response rates and sustained outcomes, and are associated with adverse side effects.

Background

Dr Liknaitzky holds numerous academic research positions, investigating the use of novel psychiatric agents. He has appointments at St Vincent's Hospital in Melbourne, Deakin University, Macquarie University, and Odyssey House Victoria. Dr Liknaitzky earned an Honours in Neuroscience and a PhD in Psychology from the University of Melbourne. His work examines mechanisms of mental illness and treatment development primarily within depression, anxiety, and addiction research.

ENDS

The release of this announcement has been approved for issue by IHL's Board of Directors. For further details on the announcement, interested parties should contact:

Mr Joel Latham, Managing Director and Chief Executive Officer

P: +61 409 840 786

E: joel@incannex.com.au



Date: 22nd September 2020
ASX Announcement (ASX: IHL)

About Incannex Healthcare Limited (ASX: IHL)

Incannex Healthcare Limited (IHL.ASX) is developing unique medicinal cannabis products for the treatment of Obstructive Sleep Apnoea (OSA), Traumatic Brain Injury (TBI)/Concussion, Acute Respiratory Distress Syndrome (ARDS) and Temporomandibular Joint Disorder (TMD). FDA registration, where being sought, is subject to clinical success.

Each indication represents major global markets and currently have no existing registered pharmacotherapy (drug) treatment, raising the possibility of patients receiving Government subsidies for products that demonstrate suitable safety and efficacy profiles in clinical trials.

There is an established body of research validating the hypothesis for the cannabinoids being used in Incannex's chosen therapeutic areas and IHL has a strong patent filing strategy (as announced "IHL files cannabinoid patent over IHL-216A for TBI" 04th October, 2019 and "IHL Files Patent over IHL-42X for OSA" 06th of December, 2019) as it develops its products in conjunction with its medical advisory board.

Further to its clinical programs, Incannex has its Australian license to import, export and distribute medicinal cannabis products and has launched a line of cannabinoid oil products. The cannabis-based oils are sold under Incannex's product supply and distribution agreement with Cannvalate Pty Ltd, which is the largest network of cannabis medicine prescribers in Australia and a major shareholder of IHL.

Website: www.incannex.com.au

Investors: investors@incannex.com.au

For personal use only